Cargando…
Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting
Antibody-Drug Conjugates (ADCs) have rapidly expanded in the clinic, with 7 new approvals in 3 years. For solid tumors, high doses of ADCs improve tissue penetration and efficacy. These doses are enabled by lower drug-to-antibody ratios and/or co-administration of unconjugated antibody carrier doses...
Autores principales: | Evans, Reginald, Thurber, Greg M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090802/ https://www.ncbi.nlm.nih.gov/pubmed/35538109 http://dx.doi.org/10.1038/s41598-022-11648-0 |
Ejemplares similares
-
Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?
por: Nessler, Ian, et al.
Publicado: (2018) -
Avidity in antibody effector functions and biotherapeutic drug design
por: Oostindie, Simone C., et al.
Publicado: (2022) -
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020) -
IgY Antibodies from Birds: A Review on Affinity and Avidity
por: Pacheco, Bianca Lisley Barboza, et al.
Publicado: (2023) -
Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)